Back to news

HealthEquity Reports Second Quarter Ended July 31, 2026 Financial Results

Globe Newswire27/08/202612:00
0
Whiz Insights

Highlights of the second quarter include:

  • Net income increased 10% to $65.6 million, and net income margin increased to 19% from 18% last year.
  • Adjusted EBITDA increased 11% to $167.0 million, and Adjusted EBITDA margin increased to 48% from 46% last year.
  • Revenue increased 8% to $350.7 million.
  • Net income per diluted share rose 15% to $0.78 from $0.68 one year ago, and non-GAAP net income per diluted share increased 15% to $1.24.
  • Total HSA Assets grew 14% to $37.9 billion.
  • Returned $108.1 million to shareholders through stock repurchases. DRAPER, Utah, Aug. 27, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) ("HealthEquity" or the "Company"), the largest independent health savings account ("HSA") custodian by account volume and a leader in consumer-directed benefits ("CDBs"), today announced financial results for its second quarter ended July 31, 2026.

"HealthEquity delivered a record-setting second quarter, with record Adjusted EBITDA margin of 48%, record HSA accounts of 10.7 million and record HSA Assets of nearly $38 billion," said Scott Cutler, President and CEO of HealthEquity. "These results reflect strong execution across the business and the durability of our model as growth comes from more places, member relationships deepen and technology-enabled efficiency improves how we serve members and clients. This momentum gives us confidence to raise fiscal 2027 guidance and enter the second half focused on scaling efficiently and creating long-term value."

Second quarter financial results

Revenue for the second quarter ended July 31, 2026 was $350.7 million, an increase of 8% compared to $325.8 million for the second quarter ended July 31, 2025. Revenue this quarter included: service revenue of $124.4 million, custodial revenue of $175.9 million, and interchange revenue of $50.4 million.

Net income was $65.6 million, or $0.78 per diluted share, for the second quarter ended July 31, 2026, compared to $59.9 million, or $0.68 per diluted share, for the second quarter ended July 31, 2025. Net income margin was 19% for the second quarter ended July 31, 2026, compared to 18% for the second quarter ended July 31, 2025.

Non-GAAP net income was $103.8 million, or $1.24 per diluted share, for the second quarter ended July 31, 2026, compared to $94.6 million, or $1.08 per diluted share, for the second quarter ended July 31, 2025.

Adjusted EBITDA was $167.0 million for the second quarter ended July 31, 2026, an increase of 11% compared to the second quarter ended July 31, 2025. Adjusted EBITDA was 48% of revenue, compared to 46% for the second quarter ended July 31, 2025.

Account and asset metrics

New HSAs from sales were 202 thousand, an increase of 24% compared to the second quarter ended July 31, 2025. HSAs as of July 31, 2026 were 10.7 million, an increase of 8% year over year, including 0.9 million HSAs with investments, an increase of 20% year over year. Total Accounts as of July 31, 2026 were 17.8 million, including 7.0 million complementary CDBs.

Total HSA Assets as of July 31, 2026 were $37.9 billion, an increase of 14% year over year. Total HSA Assets included $17.4 billion of HSA cash and $20.6 billion of HSA investments. Client-held funds, which are deposits held on behalf of our Clients to facilitate administration of our CDBs, and from which we generate custodial revenue, were $0.9 billion as of July 31, 2026.

Stock repurchase program

The Company repurchased 1.2 million shares of its common stock for $108.1 million during the second quarter ended July 31, 2026. As of July 31, 2026, $948.4 million of common stock remained authorized for repurchase under the stock repurchase program.

Business outlook

For the fiscal year ending January 31, 2027, management is raising guidance and now expects revenues of $1.411 billion to $1.421 billion. Its outlook for net income is between $242 million and $248 million, resulting in net income of $2.88 to $2.96 per diluted share. Its outlook for non-GAAP net income, calculated using the method described below, is between $392 million and $398 million, resulting in non-GAAP net income per diluted share of $4.66 to $4.73 (based on an estimated 84 million diluted weighted-average shares outstanding). Management expects Adjusted EBITDA of $628 million to $636 million.

See “Non-GAAP financial information” below for definitions of our Adjusted EBITDA and non-GAAP net income. A reconciliation of the non-GAAP financial measures used throughout this release to the most comparable GAAP financial measures is included with the financial tables at the end of this release.

Conference call

HealthEquity management will host a conference call at 8:30 a.m. (Eastern Time) on Thursday, August 27, 2026 to discuss the fiscal 2027 second quarter financial results. The conference call will be accessible by dialing 1-833-630-1956, or 1-412-317-1837 for international callers, and referencing conference ID "HealthEquity." A live audio webcast of the call will be available on the investor relations section of our website at http://ir.healthequity.com.

Non-GAAP financial information

To supplement our financial information presented on a GAAP basis, we disclose non-GAAP financial measures, including Adjusted EBITDA, non-GAAP net income, and non-GAAP net income per diluted share.

  • Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items.
  • Non-GAAP net income is calculated by adding back to GAAP net income before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate.
  • Non-GAAP net income per diluted share is calculated by dividing non-GAAP net income by diluted weighted-average shares outstanding. Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP and should not be considered as a substitute for, or superior to, GAAP results. We believe that these non-GAAP financial measures provide useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. The Company cautions investors that non-GAAP financial information, by its nature, departs from GAAP; accordingly, its use can make it difficult to compare current results with results from other reporting periods and with the results of other companies. In addition, while amortization of acquired intangible assets is being excluded from non-GAAP financial measures, the revenue generated from those acquired intangible assets is not excluded. Whenever we use these non-GAAP financial measures, we provide a reconciliation of the applicable non-GAAP financial measure to the most closely applicable GAAP financial measure. Investors are encouraged to review the related GAAP financial measures and the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measure as detailed in the tables below.

About HealthEquity

HealthEquity and its subsidiaries administer HSAs and other consumer-directed benefits for more than 17 million accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our mission to save and improve lives by empowering healthcare consumers. For more information, visit www.healthequity.com.

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our industry, business strategy, plans, goals and expectations concerning our markets and market position, product expansion, future operations, expenses and other results of operations, revenue, margins, profitability, acquisition synergies, future efficiencies, tax rates, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words “may,” “believes,” “intends,” “seeks,” “aims,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,” “future” and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release.

Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to be correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, risks related to the following:

  • our ability to adequately place and safeguard our custodial assets, or the failure of any of our depository or insurance company partners;
  • our ability to compete effectively in a rapidly evolving healthcare and benefits administration industry;
  • our dependence on the continued availability and benefits of tax-advantaged HSAs and other CDBs;
  • the impact of fraudulent account activity involving our member accounts or our third-party service providers on our reputation and financial results;
  • our ability to successfully identify, acquire and integrate additional portfolio purchases or acquisition targets;
  • the significant competition we face and may face in the future, including from those with greater resources than us;
  • our reliance on the availability and performance of our technology and communications systems;
  • potential future cybersecurity breaches of our technology and communications systems and other data interruptions, including resulting costs and liabilities, reputational damage and loss of business;
  • the current uncertain healthcare environment, including changes in healthcare programs and expenditures and related regulations;
  • our ability to comply with current and future privacy, healthcare, tax, ERISA, investment adviser and other laws applicable to our business;
  • our reliance on partners and third-party vendors for distribution and important services;
  • our ability to develop and implement updated features for our technology platforms and communications systems; and
  • our reliance on our management team and key team members. For a detailed discussion of these and other risk factors, please refer to the risks detailed in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the fiscal year ended January 31, 2026 and subsequent periodic and current reports. Past performance is not necessarily indicative of future results. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor Relations Contact Richard Putnam 801-727-1000 rputnam@healthequity.com

HealthEquity, Inc. and subsidiaries Condensed consolidated balance sheets

(in thousands, except par value)July 31, 2026January 31, 2026
(unaudited)
Assets
Current assets
Cash and cash equivalents $256,003$318,927
Accounts receivable, net of allowance for doubtful accounts of $1,067 and $924 as of July 31, 2026 and January 31, 2026, respectively122,193123,696
Prepaid expenses and other current assets82,00869,658
Total current assets460,204512,281
Property and equipment, net4,8233,177
Operating lease right-of-use assets32,87436,310
Intangible assets, net1,047,7971,097,172
Goodwill1,648,1451,648,145
Other assets77,52083,247
Total assets $3,271,363$3,380,332
Liabilities and stockholders’ equity
Current liabilities
Accounts payable $8,592$12,159
Accrued compensation37,91360,392
Accrued liabilities97,30074,388
Operating lease liabilities9,9709,911
Total current liabilities153,775156,850
Long-term liabilities
Long-term debt, net of issuance costs931,062957,379
Operating lease liabilities, non-current29,98434,190
Other long-term liabilities73,99931,007
Deferred tax liability92,43393,710
Total long-term liabilities1,127,4781,116,286
Total liabilities1,281,2531,273,136
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of July 31, 2026 and January 31, 2026, respectively
Common stock, $0.0001 par value, 900,000 shares authorized, 82,909 and 85,007 shares issued and outstanding as of July 31, 2026 and January 31, 2026, respectively88
Additional paid-in capital1,896,5711,916,989
Accumulated earnings162,583195,906
Accumulated other comprehensive loss (69,052)(5,707)
Total stockholders’ equity1,990,1102,107,196
Total liabilities and stockholders’ equity $3,271,363$3,380,332
Health Equity, Inc. and subsidiaries Condensed consolidated statements of operations (unaudited) Three months ended July 31, Six months ended July 31, (in thousands, except per share data)2026202520262025
Revenue Service revenue$124,444$117,873$247,376$237,657
Custodial revenue175,936159,876350,270316,331
Interchange revenue50,35248,086107,727102,691
Total revenue350,732325,835705,373656,679
Cost of revenue Service costs73,17075,156151,496163,161
Custodial costs12,08311,13723,73821,884
Interchange costs7,5256,94715,87314,728
Total cost of revenue92,77893,240191,107199,773
Gross profit257,954232,595514,266456,906
Operating expenses Sales and marketing23,21519,92250,04845,906
Technology and development73,92364,804141,690126,240
General and administrative34,86929,99066,00055,526
Amortization of acquired intangible assets26,28627,00152,80154,003
Merger integration9711,2662,0842,541
Total operating expenses159,264142,983312,623284,216
Income from operations98,69089,612201,643172,690
Other expense Interest expense(12,605)(14,955)(25,193)(29,813)
Other income, net1,7803,3913,8286,124
Total other expense(10,825)(11,564)(21,365)(23,689)
Income before income taxes87,86578,048180,278149,001
Income tax provision22,22118,19445,21635,232
Net income$65,644$59,854$135,062$113,769
Net income per share:
Basic$0.79$0.69$1.61$1.31
Diluted$0.78$0.68$1.60$1.29
Weighted-average number of shares used in computing net income per share:
Basic83,37486,55083,88586,601
Diluted84,01487,74684,57888,153
Health Equity, Inc. and subsidiaries Condensed consolidated statements of comprehensive income (unaudited) Three months ended July 31, Six months ended July 31, (in thousands)2026202520262025
Net income$65,644$59,854$135,062$113,769
Other comprehensive income (loss) Cash flow hedges Net unrealized gains (losses)(37,322)203(63,219)203
Reclassification of net (gains) losses included in net income22(126)
Net change, net of income tax benefit (expense) of $12,135, $(70), $20,598, and $(70), respectively(37,300)203(63,345)203
Total other comprehensive income (loss)(37,300)203(63,345)203
Comprehensive income$28,344$60,057$71,717$113,972
Health Equity, Inc. and subsidiaries Condensed consolidated statements of cash flows (unaudited) Six months ended July 31, (in thousands)20262025
Cash flows from operating activities:
Net income$135,062$113,769
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization80,16977,195
Stock-based compensation41,61633,404
Amortization of debt discount and issuance costs558533
Amortization of gains on derivatives(168)
Deferred taxes19,32130,711
Changes in operating assets and liabilities:
Accounts receivable, net1,5036,842
Prepaid expenses and other current and non-current assets(12,581)(20,650)
Operating lease right-of-use assets3,4363,339
Accrued compensation(21,095)(35,032)
Accounts payable, accrued liabilities, and other current liabilities(13,595)(3,785)
Operating lease liabilities, non-current(4,206)(3,951)
Other long-term liabilities3,665(1,771)
Net cash provided by operating activities233,685200,604
Cash flows from investing activities:
Capitalized software development costs(30,720)(26,464)
Purchases of property and equipment(1,340)(859)
Settlement of derivatives, net(7,759)
Net cash used in investing activities(39,819)(27,323)
Cash flows from financing activities:
Repurchases of common stock(231,054)(125,810)
Principal payments on long-term debt(26,875)(50,000)
Settlement of client-held funds obligation, net480596
Proceeds from exercise of common stock options65910,446
Net cash used in financing activities(256,790)(164,768)
Increase (decrease) in cash and cash equivalents(62,924)8,513
Beginning cash and cash equivalents318,927295,948
Ending cash and cash equivalents$256,003$304,461

HealthEquity, Inc. and subsidiaries Condensed consolidated statements of cash flows (unaudited) (continued) Six months ended July 31, (in thousands) 2026 2025 Supplemental cash flow data: Interest expense paid in cash $ 23,350 $ 28,362 Income tax payments, net 35,586 6,507 Supplemental disclosures of non-cash investing and financing activities: Capitalized software development costs included in accounts payable, accrued liabilities, or accrued compensation 3,434 3,380 Purchases of property and equipment included in accounts payable or accrued liabilities 1,294 155 Repurchases of common stock included in accrued liabilities 3,255 1,246 Exercise of common stock options receivable 57 —

Stock-based compensation expense (unaudited) Total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive income is as follows:
Three months ended July 31, Six months ended July 31, (in thousands)2026202520262025
Cost of revenue$2,713$3,114$5,500$6,501
Sales and marketing3,2291,5297,7536,399
Technology and development6,1785,73210,13111,652
General and administrative10,0908,69318,2328,852
Total stock-based compensation expense$22,210$19,068$41,616$33,404
Total Accounts (unaudited) (in thousands, except percentages) July 31,2026
July 31,2025%
Change January 31,2026
HSAs10,7399,9898%10,570
New HSAs from sales-
Quarter-to-date20216324%553
New HSAs from sales-
Year-to-date37431220%1,040
New HSAs from acquisitions-
Year-to-date
*
HSAs with investments93978220%832
CDBs7,0167,153(2)%7,221
Total Accounts17,75517,1424%17,791
Average Total Accounts-
Quarter-to-date17,71017,0444%17,462
Average Total Accounts-
Year-to-date17,77217,0834%17,220
  • Not meaningful
HSA Assets (unaudited) (in millions, except percentages) July 31,2026
July 31,2025%
Change January 31,2026
HSA cash$17,369$17,0352%$17,982
HSA investments20,55216,10228%18,482
Total HSA Assets37,92133,13714%36,464
Average daily HSA cash-
Quarter-to-date17,38817,0172%17,090
Average daily HSA cash-
Year-to-date17,54717,1492%17,082

HSA cash maturity schedule The following table summarizes the amount of HSA cash held by our depository partners and insurance company partners that is expected to reprice by fiscal year and the respective average annualized yield currently earned on that HSA cash as of July 31, 2026: Year ending January 31, (in billions, except percentages) HSA cash expected to reprice Average annualized yield Remainder of 2027 $ 2.3 1.5% 2028 2.5 4.0% 2029 1.8 3.8% 2030 2.3 4.4% Thereafter 7.8 4.4% Total (1) $ 16.7 3.9%

(1)  Excludes $0.7 billion of HSA cash held in floating-rate contracts as of July 31, 2026.

Client-held funds (unaudited) (in millions, except percentages) July 31,2026
July 31,2025%
Change January 31,2026
Client-held funds$931$81814%$1,090
Average daily Client-held funds-
Quarter-to-date9368846%879
Average daily Client-held funds-
Year-to-date98689310%864
Reconciliation of net income to Adjusted EBITDA (unaudited) Three months ended July 31, Six months ended July 31, (in thousands)2026202520262025
Net income$65,644$59,854$135,062$113,769
Interest income(1,760)(3,364)(3,647)(6,097)
Interest expense12,60514,95525,19329,813
Income tax provision22,22118,19445,21635,232
Depreciation and amortization15,66911,45327,36823,192
Amortization of acquired intangible assets26,28627,00152,80154,003
Stock-based compensation expense22,21019,06841,61633,404
Merger integration expenses9711,2662,0842,541
Amortization of incremental costs to obtain a contract2,1391,9514,2553,877
Costs associated with unused office space1,0167231,7021,575
Other(20)(27)(181)(27)
Adjusted EBITDA$166,981$151,074$331,469$291,282
Net income and Adjusted EBITDA as a percentage of revenue (unaudited) Three months ended July 31, Six months ended July 31, (in thousands, except20262025
$ Change % Change20262025
$ Change % Change percentages) Net income$65,644$59,854$5,79010%$135,062$113,769$21,29319%
As a percentage of revenue19%18%19%17%
Adjusted EBITDA$166,981$151,074$15,90711%$331,469$291,282$40,18714%
As a percentage of revenue48%46%47%44%
Reconciliation of net income outlook to Adjusted EBITDA (unaudited) Outlook for the year ending (in millions) January 31,2027
Net income$242-248
Interest income(7)
Interest expense50
Income tax provision81-83
Depreciation and amortization54
Amortization of acquired intangible assets104
Stock-based compensation expense87
Merger integration expenses5
Amortization of incremental costs to obtain a contract9
Costs associated with unused office space3
Adjusted EBITDA$628-636

Note: Values presented may not calculate due to rounding.

Reconciliation of net income to non-GAAP net income (unaudited) Three months ended July 31, Six months ended July 31, (in thousands, except per share data)2026202520262025
Net income$65,644$59,854$135,062$113,769
Income tax provision22,22118,19445,21635,232
Income before income taxes-
GAAP87,86578,048180,278149,001
Non-GAAP adjustments:
Amortization of acquired intangible assets26,28627,00152,80154,003
Stock-based compensation expense22,21019,06841,61633,404
Merger integration expenses9711,2662,0842,541
Costs associated with unused office space1,0167231,7021,575
Total adjustments to income before income taxes-
GAAP50,48348,05898,20391,523
Income before income taxes-
Non-GAAP138,348126,106278,481240,524
Income tax provision-
Non-GAAP(1)34,58631,52669,62060,130
Non-GAAP net income103,76294,580208,861180,394

Diluted weighted-average shares 84,014 87,746 84,578 88,153 GAAP net income per diluted share $ 0.78 $ 0.68 $ 1.60 $ 1.29 Non-GAAP net income per diluted share $ 1.24 $ 1.08 $ 2.47 $ 2.05

(1) The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.

Reconciliation of net income outlook to non-GAAP net income outlook (unaudited) Outlook for the year ending (in millions, except per share data) January 31,2027
Net income$242-248
Income tax provision81-83
Income before income taxes-
GAAP323-331
Non-GAAP adjustments:
Amortization of acquired intangible assets104
Stock-based compensation expense87
Merger integration expenses5
Costs associated with unused office space3
Total adjustments to income before income taxes-
GAAP199
Income before income taxes-
Non-GAAP522-530
Income tax provision-
Non-GAAP(1)131-133
Non-GAAP net income$392-398
Diluted weighted-average shares84
GAAP net income per diluted share$2.88 - 2.96
Non-GAAP net income per diluted share$4.66 - 4.73

Note: Values presented may not calculate due to rounding.

(1) The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.

Certain terms Term Definition HSA Health Savings Account, which is a financial account through which consumers spend and save long-term for healthcare on a tax-advantaged basis. CDB Consumer-directed benefits offered by employers, including flexible spending and health reimbursement arrangements (“FSAs” and “HRAs”), Consolidated Omnibus Budget Reconciliation Act (“COBRA”) administration, commuter and other benefits. HSA member Consumers with HSAs that we serve. Total HSA Assets HSA members’ custodial cash assets held by our federally insured depository partners and our insurance company partners. Total HSA Assets also includes HSA members' investments held by our custodial investment fund partner. Client Our employer clients. Total Accounts The sum of HSAs and CDBs on our platforms. Client-held funds Deposits held on behalf of our Clients to facilitate administration of our CDBs. Network Partner Our health plan partners, benefits administrators, and retirement plan recordkeepers. Adjusted EBITDA Earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items. Non-GAAP net income Calculated by adding back to GAAP net income before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate. Non-GAAP net income per diluted share Calculated by dividing non-GAAP net income by diluted weighted-average shares outstanding.

GlobeNewswire, Inc. 2026

Article ID: nGNX5BCXQJ Archive began May 2026 · Available for up to 365 days after publication